A trial fibrillation (AF), the most common arrhythmia in clinical practice, remains associated with significant morbidity and mortality. 1 Catheterbased ablation targeting pulmonary vein (PV) isolation is increasingly performed for rhythm control in clinical practice. 2 One potentially serious complication of AF ablation is the development of PV stenosis (PVS), 3 which continues to be observed despite the evolution of ablation strategies. Potential contributing factors for developing PVS include delivery of ablation lesions inside the PVs or ostially, vein size, or inappropriate energy levels. [4] [5] [6] [7] [8] Little is known about the clinical course, outcomes, management, and long-term follow-up of patients with severe PVS from a prior AF ablation procedure. More specifically, in patients with severe PVS and arrhythmia recurrence, little is known about the clinical management of the arrhythmia, safety, and role of redo ablations, especially in the presence of pulmonary venous stents.
In this study, we report the Cleveland Clinic experience, spanning the course of 16 years, with the outcomes and management of patients with severe PVS from prior AF ablation, with focus on both the clinical outcomes and feasibility and efficacy of redo ablations.
METHODS
This study was approved by the Cleveland Clinic Institutional Review Board. Informed consents were obtained before the mapping and ablation procedures. The data, analytic methods, and study materials will not be made available to other researchers.
Study Population
All patients undergoing AF ablation at our institution between 2000 and 2015 were enrolled in a prospectively
WHAT IS KNOWN?
• Pulmonary vein stenosis (PVS) remains a feared complication of atrial fibrillation ablation.
• Little is known about outcomes in patients with severe PVS, especially about repeat ablations.
WHAT THE STUDY ADDS?
• In a large prospective cohort undergoing routine cardiac computed tomographic scans 3 to 6 months after atrial fibrillation ablation procedures, the incidence of severe PVS remains low but associated with significant morbidity.
• The left superior pulmonary vein appears to be the most common site of severe stenosis.
• Pulmonary venous interventions resulted in improvement of symptoms.
• The majority of patients who developed severe PVS remained arrhythmia free during follow-up, whereas 20% had arrhythmia recurrences.
• Redo ablation in the setting of severe PVS or stented veins is feasible and PV conduction recovery was noted in most of the veins with severe PVS or stents. There is risk of circular mapping catheter entrapment, and we suggest avoiding its use.
• Redo ablation in the setting of severe PVS or stented veins allows rhythm control without significant risk of stenosis progression with careful antral ablation. 
Conduction Recovery
All except 3 of the severely stenosed or stented veins PV interventions (n=43) with improvement of symptoms maintained AF ablation data registry and screened for eligibility for the current study. In our practice, we routinely obtain cardiac computed tomographic (CT) scans at 3 to 6 months after ablation to screen for PVS. Contrast-enhanced spiral CT scanning, including prospective gating with overlapping 1.00-to 1.25-mm-thick images from carina to apex for multiplanar reconstructions or maximal intensity projections, are typically used. On the basis of CT scans, the degree of PVS was graded as mild, moderate, or severe, which were defined as luminal narrowing of <50%, 50% to 70%, or >70%, respectively. All consecutive patients with confirmed severe PVS from a prior ablation at our institution were identified and were included in the current study. In addition, we assessed the safety and role of repeat ablation procedures in patients with recurrent drug-refractory arrhythmias and confirmed severe PVS regardless of whether the initial ablation was at our institution or elsewhere. In our practice, we perform CT scans routinely before repeat ablations in patients with prior failed ablation at other institutions to assess for PVS and further guide clinical management.
Clinical Course and Follow-Up
Clinical and follow-up data were collected before the index ablation procedures, on the day of ablation, and subsequent follow-up visits and were continuously updated in electronic medical records.
As previously mentioned, CT scans are routinely obtained in all patients, 3 to 6 months after the ablation procedures to assess for PVS. All patients with severe PVS were referred for consideration of PV stenting or balloon dilation.
All clinical documentation, including telephone encounters or other forms of communication with the patients or their referring physicians, such as letters, was documented electronically. All patients received rhythm transmitters (Pacetrak plus, Mednet, NJ) for a minimum of 3 months after the procedure and recorded whenever symptomatic and on a weekly basis even when asymptomatic. Additional event recorder monitoring was obtained beyond the 3-month period for patients with documented arrhythmia and those who developed symptoms suggestive of arrhythmia during the 3-month period. Interrogation of implanted devices, whenever available, was also used to assess for arrhythmia recurrences. Patients had scheduled clinical visits, 12-lead ECGs, and 24-hour Holters at 3, 6, and 12 months after the procedure. More frequent follow-up visits were scheduled as clinically indicated such as in patients who required further management of antiarrhythmic medications or anticoagulants. Atrial arrhythmias that occurred during the first 3 months after ablation were not counted as recurrences because this was considered a blanking period.
Arrhythmia recurrence was defined as electrocardiographic documentation of an atrial tachyarrhythmia, lasting ≥30 s, on a 12-lead ECG, event recording, or Holter monitor recording with or without symptoms.
All patients with severe PVS and recurrent arrhythmia were generally managed medically initially, and repeat ablations were subsequently considered in those who continued to have drug-refractory arrhythmias. Repeat CT scans were performed after the redo ablation procedures to assess for progression of PVS.
Radiofrequency Ablation Protocol
Our AF ablation protocol and periprocedural anticoagulation strategies were previously reported in detail. [9] [10] [11] In general and when possible, antiarrhythmic medications were stopped 4 to 5 half-lives before ablation. All ablation procedures were performed without interruption of therapeutic anticoagulation. Intracardiac echocardiography was used to guide transseptal access and catheter manipulation and to monitor for complications. A circular mapping catheter (Lasso) was used to guide PV and left atrial ablation. Care is taken to ablate antrally especially in patients with prior PVS. In patients with prior PV stents in place, PV conduction recovery at the antrum was assessed and targeted with ablation while avoiding ablation or catheter manipulation at the stent level. In addition to antral ablations to isolate the PVs, ablation was performed at the posterior wall and septal to the right-sided veins. Additional ablations, including linear ablations or superior vena cava ablation, were performed at the discretion of the operating electrophysiologist.
Statistical Analyses
Descriptive statistics were calculated using the statistical software SPSS version 17 (IBM; Armonk, NY). Numbers are presented as n (%), mean±SD, or median (interquartile range), as appropriate.
RESULTS

Study Population
A total of 10 368 patients underwent AF ablation at our institution during the study period (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) and were enrolled in our prospectively maintained AF ablation data registry. From this group of patients, all 52 (0.5%) consecutive patients who developed severe PVS after the ablation procedures were included in the primary analysis of the current study (Table) . The mean age in this cohort was 56 years old, and the majority of patients (85%) were men. Before the ablation procedures which resulted in PVS, 16 patients (32%) had a previous AF catheter ablation and 2 (4%) had a prior MAZE procedure. In all, there were a total of 63 severely stenosed PVs in 52 patients (42 patients with 1 severe PVS, 9 with 2, and 1 with 3 PVS). The distribution of severely stenosed veins (Figure 1 ) was as follows: 51% left superior PV, 36% left inferior PV, 6% left common PV, 5% right inferior PV, and 2% right superior PV. Concomitant PVS in this cohort included 16 moderate PVS in 13 patients and 11 mild PVS in 11 patients.
Pulmonary Venous Interventions for Severe PVS
Pulmonary venous interventions were performed in 43 patients (83%) and consisted of PV stenting in 37 patients and balloon dilatation in 6 patients. The remaining 9 patients were managed conservatively. A total of 53 veins were stented in 37 patients, and 9 veins (17%) in 9 patients had stent restenosis, which required reintervention within median time of 14 months. Among 43 patients with severe PVS who had PV interventions, symptoms leading to interventions were the following: shortness of breath (46%, n=24), decrease in exercise capacity (42%, n=22), cough (25%, n=13), chest pain or discomfort (9%, n=5), and hemoptysis (5%, n=3). Baseline echocardiographic data were available for 36 patients with severe PVS before PV interventions and showed a mean left ventricular ejection fraction of 57±7% and normal right ventricular systolic function in all patients. Right heart catheterization (n=37) before PV interventions showed an average right atrial pressure of 10±3 mm Hg with mean pulmonary artery pressure of 24±6 mm Hg and pulmonary wedge pressure of 17±6 mm Hg. Lung perfusion scans were obtained in 29 patients and showed perfusion abnormalities in involved segments in 18 patients.
After PV interventions, treated patients had complete resolution of chest pain and hemoptysis, whereas some patients reported residual symptoms: 7% (n=4) had shortness of breath, 5% (n=3) had decrease in exercise capacity, and 4% (n=2) had persistent cough. Generally speaking and based on patient's subjective assessment and clinical documentation, all patients had improvement in their quality of life after the interventions. Of the 18 patients with perfusion abnormalities on lung perfusion scans, 16 were found to have improvement in lung perfusion patterns on post-PV interventions scans, based on qualitative assessment by interpreting radiologists.
There were no procedure-related deaths. Five patients experienced major complications from pulmonary venous interventions. Three patients had a pulmonary venous tear that required emergent surgical repair. All survived with no long-term disability. One patient had a procedure-related stroke which occurred intraprocedurally but recovered completely with no residual deficit on follow-up after 1 month. The last patient with a major procedure-related complication had phrenic nerve injury which recovered partially on follow-up at 6 months. Three patients had small groin hematomas which did not require interventions.
Recurrent Arrhythmia and Management in Patients With Severe PVS
Patients with severe PVS (n=52) were followed up for a median of 25 months (25th-75th percentile, 18-125) after the ablation procedures which resulted in PVS. During the follow-up period, 41 patients (79%) remained arrhythmia free and 11 patients (21%) had arrhythmia recurrence. The recurrent arrhythmias were AF in 6 patients and atrial flutter in 5. The median time to arrhythmia recurrence was 15 months (25th-75th percentile, 6-63). All 11 patients with recurrent arrhythmia were symptomatic, and a rhythm control strategy was followed. This was achieved with dofetilide in 4 patients, and 7 patients required repeat ablation procedures.
Redo Ablations in Patients With Severe PVS or PV Stents
In addition to 7 patients with severe PVS from the primary cohort, repeat ablations were performed in 8 patients with severe PVS and symptomatic drug- refractory arrhythmia recurrence after a prior ablation at other centers. In total, 15 patients with severe PVS underwent repeat ablation during the study period. At the time of redo ablations, 10 of 15 patients had PV stents in place. These stents (n=20) were located as follows: 10 left superior PV, 7 left inferior PV, and 3 right superior PV. Concomitant PVS included moderate stenosis involving 5 veins in 3 patients and mild stenosis involving 2 veins in 2 patients.
At the time of redo ablations, conduction recovery was noted in all but 3 of the severely stenosed or stented PVs and areas with recovery were targeted with antral ablations with successful isolation. An atypical flutter was mapped in 1 patient to the roof in the vicinity of an left superior PV stent.
There were no procedure-related deaths, stroke, or cardiac perforation in redo ablations. In all patients with prior stents, the stents appeared to protrude into the left atrial cavity (Figure 2) . Lasso entrapment within left superior PV stents occurred in 2 patients. In 1 patient, a balloon was inflated in the stent to provide countertraction, whereas the Lasso was pulled from within the stent struts. In the other patient (Figure 3) , the transseptal sheath was advanced to the stent level for countertraction to free the Lasso but the distal nippled portion of the Lasso got detached and embolized. Imaging with head CT confirmed that the brain was not the site of embolization. There were no clinical consequences in either patients, and the stents remained stable in their position.
Three patients underwent preplanned stenting after redo ablations. Cardiac CT scans, 3 to 6 months after redo ablations, showed progression of concomitant PVS in 1 patient from moderate to severe requiring stenting.
Over a median follow-up of 30 months (25th-75th percentile, 4-33) after redo ablations (n=15), all but 2 patients remained arrhythmia free but 6 of the remaining 13 were maintained on antiarrhythmic drugs (AAD) because of their prior clinical history.
DISCUSSION
In a large prospective cohort undergoing routine cardiac CT scans 3 to 6 months after AF ablation procedures and spanning the course of 16 years at our center, only 52 of 10 368 (0.5%) patients developed severe PVS. The left superior PV appeared to be the most common site of severe stenosis. Pulmonary venous interventions were required in 43 of 52 patients, and 5 experienced major complications including need for cardiac surgery for pulmonary venous tear in 3 of them. The majority of patients who developed severe PVS remained arrhythmia free during follow-up, whereas 20% of them had arrhythmia recurrences. In a secondary cohort investigating the safety and efficacy of redo ablation in the setting of severe PVS or stented veins (n=15, 8 from index ablation at outside institutions), PV conduction recovery was noted in most of the veins with severe PVS or stents. In redo procedures, antral ablations to reisolate the veins allowed arrhythmia control without progression of PVS in most patients. Lasso entrapment within PV stents occurred in 2 patients but was eventually freed without needing cardiac surgery.
To our knowledge, this is the first study to report on the long-term outcomes in patients with severe PVS from prior AF ablation. With routine CT scanning at 3 to 6 months after the ablation procedures, only a small number of patients developed severe PVS but its occurrence carried significant morbidity. The incidence of PVS has fallen dramatically over the years primarily because of changes in ablation strategies. 3, 12 In our practice, we use a roving circular mapping catheter technique with real-time visualization by intracardiac echocardiography (ICE) to ensure antral ablations. We think that ICE guided ablations contributed to low rates of severe PVS in this cohort.
In today's clinical practice, PVS continues to be observed. The left-sided PVs have traditionally been more likely to be involved, [13] [14] [15] [16] which could be related to need for ostial ablation at the anterior ridge without sufficient extension of the ablation set to the posterior wall. Ablation within the veins anteriorly could be as well a contributing factor when relying purely on 3-dimensional mapping with potential errors in registration. Real-time ICE is useful in this setting to observe both the circular mapping catheter and the ablation catheter. In our practice, in addition to ICE imaging, we save snapshots of the circular mapping catheter at the vein ostia using 3-dimensional mapping and this is confirmed with ICE to provide a landmark that must not be violated during radiofrequency applications. We also mark the anterior ridge of the left-sided veins by assessing catheter behavior/movement in 3-dimensional mapping.
In this cohort, pulmonary venous interventions were required in most patients with severe PVS with stenting being the preferred modality. Although most studies addressing PVS in the literature assessed pulmonary venous interventions such as balloon dilatation or stenting, 17, 18 little is known about the clinical arrhythmia outcomes in these patients and their management, especially about repeat ablations. The current study showed that although most patients remained arrhythmia free, those with recurrent symptomatic arrhythmia represent a clinical challenge requiring redo ablations in many cases.
In our experience, redo ablations in patients with severe PVS allowed rhythm control in most patients and for the most part did not result in progression of stenosis. Care needs to be taken to ablate antrally in these patients. Although PV conduction recovery is seen in most patients undergoing repeat ablation procedure for recurrent arrhythmia, [19] [20] [21] the observation of residual antral signals in severely stenosed veins could reflect more ostial ablations during the index ablation procedures. It is possible that antral triggers could have contributed to arrhythmia recurrences in this setting which would be the explanation of improved outcomes with redo ablations. In fact, antral PV isolation has been shown to be superior to ostial PV isolation for rhythm control. 22 In patients with PV stents in place, antral signals were found and ablated in most of them. Despite all precautions to avoid Lasso entrapment in the stents during catheter manipulation, this still occurred. Although this did not result in adverse clinical outcomes, Lasso entrapment could have indicated open heart surgery. Lasso entrapment in cardiac structures has been previously reported. 23, 24 In the case of PV stents in place, we suggest avoiding the use of a Lasso catheter.
Study Limitations
The study has the limitations of observational study but was derived from a prospectively maintained cohort. The findings reflect the experience of a large tertiary care referral center and may not be generalized to lower volume centers. Finally, the study cohort is limited by the population size. Nonetheless, that reflects the low incidence of severe PVS but also emphasizes some clinical challenges in the care of these patients. The population size limited analyses aiming at assessing predictors of severe PVS, including year of ablation with no significant trend over the years. That being said, we think that the risk of developing severe PVS is mostly because of technical considerations including among others ostial ablation or ablation within the veins, poor intracardiac echocardiography images or errors in registration when relying completely on electroanatomical maps.
Conclusions
In a large prospective cohort undergoing routine cardiac CT scans 3 to 6 months after AF ablation procedures and spanning the course of 16 years at a tertiary care center, severe PVS was not common but remains associated with significant morbidity. Many patients with severe PVS and recurrent arrhythmia required repeat ablation procedure for rhythm control and were found to have conduction recovery at the stenosed or stented PV in most cases. Although redo ablation is feasible, care must be taken to ablate antrally to avoid stenosis progression. Finally, Lasso entrapment within PV stents was observed, and we suggest that Lasso use must be avoided.
